Preparation of water-soluble activatable chemiluminescent probe and application of water-soluble activatable chemiluminescent probe in living imaging

By developing water-soluble activateable chemiluminescent nanoprobes, the reaction of porphyrin derivatives with peroxynitrites has been used to generate near-infrared signals, which solves the problem of difficulty in detection and imaging in the prior art, and achieves high sensitivity and Chemiluminescence imaging with low background, suitable for the diagnosis of in vivo inflammation and tumors.

CN118949079APending Publication Date: 2024-11-15MENGCHAO HEPATOBILIARY HOSPITAL OF FUJIAN MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411055764.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-02
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The prior art is difficult to effectively detect and image the complex biological functions of peroxynitrite (ONOO−) in cells and organisms, especially due to its high reactive activity, short lifespan and low content, which leads to increased detection difficulty and typical Fluorescence imaging methods have problems with autofluorescence noise and low tissue penetration.

Method used

Develop a water-soluble activated chemiluminescent nanoprobe, using porphyrin derivatives as imaging and response elements, to generate near-infrared chemiluminescent signals by reacting with peroxynitrite, and synthesized by covalent linking and nanoprecipitation methods , ensure the stability of the probe and the high signal-to-noise ratio.

Benefits of technology

High sensitivity, selectivity and low background chemiluminescence imaging of peroxynitrites is achieved, reducing autofluorescence noise, improving the signal-to-noise ratio and tissue penetration of imaging, suitable for the diagnosis and imaging of in vivo inflammation and tumors .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118949079A_ABST
    Figure CN118949079A_ABST
Patent Text Reader

Abstract

The invention discloses a preparation method of a water-soluble activatable chemiluminescence imaging probe and in-vivo imaging application of the water-soluble activatable chemiluminescence imaging probe. The nanoprobe has good stability, biocompatibility and functionality, shows good selectivity, high sensitivity and rapid response chemiluminescence to ONOO, and can be used for in-vivo spontaneous chemiluminescence imaging of peroxynitrite. In addition, the nanoprobe is successfully applied to imaging of cell ONOO <-> change and endogenous ONOO <-> change of a living mouse inflammation model and a subcutaneous or in-situ hepatocellular carcinoma tumor model. In-vitro and in-vivo studies verify that the nano probe has good detection and imaging capability on ONOO, and has excellent tissue penetration depth and high signal-to-noise ratio. Therefore, the invention successfully develops an activatable chemiluminescence imaging tool which has a good application prospect in research of important peroxynitrite-related chemical and biological applications.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of chemiluminescent probes, and in particular relates to a preparation method of a water-soluble activatable chemiluminescent imaging probe and its in vivo imaging application. Background Art

[0002] Peroxynitrite (ONOO−) is one of the typical reactive nitrogen species (RNS) and is produced by the reaction of superoxide anion and nitric oxide. Peroxynitrite is highly reactive and can react with many important biological molecules in cells, such as proteins, lipids, and nucleic acids. In normal physiological processes, RNS act as key signaling molecules involved in cell signal transduction. However, the low content, short life span (about 10 ms at pH 7.4) and high reactivity of ONOO− in living systems make it difficult to detect in real-time and non-invasive modes. Therefore, it is urgent to develop effective and accurate detection methods to analyze ONOO−, which will help improve the understanding of its complex biological functions in cells and organisms.

[0003] Among them, optical imaging with non-ionizing light tissue interaction for signal reading exhibits less harmful radiation risk and shows good advantages in cost-effectiveness, non-invasiveness, high temporal and spatial resolution, playing an important role in preclinical and basic research. In the in vivo imaging of ONOO-, although many responsive fluorescent probes have been developed and good results have been achieved. However, typical fluorescence imaging methods require real-time laser excitation (especially for the most commonly used visible light probes), which has some shortcomings in imaging in living animals, such as high autofluorescence from the excitation light and low tissue penetration. In addition, most small molecule fluorescent probes have the disadvantages of poor water solubility and short emission wavelength (<600 nm), which further limits the in vivo imaging application. Chemiluminescence imaging method uses chemical reaction to emit photons and is a promising low-background in vivo optical imaging technology. Since no light excitation is required, it can effectively reduce the interference of autofluorescence noise common in fluorescent imaging probes. At present, luminol-based systems have been developed for chemiluminescence detection or imaging by reaction with H2O2 or RNS. However, the application of these probes for ONOO- in vivo imaging is still limited due to disadvantages such as low stability, poor selectivity and short-wavelength emission. Recently, some sterically hindered 1,2-dioxetane derivative probes have been reported to improve the sensitivity and selectivity of the probes. These probes utilize the chemiluminescence resonance energy transfer mechanism to red-shift the emission wavelength. However, the complexity and low reproducibility of the synthesis limit their clinical translation. Therefore, it is still challenging to develop chemiluminescent probes with good biosafety, sensitivity, selectivity, easy preparation and long near-infrared region (NIR) emission for ONOO- in vivo imaging.

[0004] In summary, developing a peroxynitrite-responsive low-background chemiluminescent imaging nanoprobe and applying it to low-background, highly sensitive, and highly selective imaging in vivo has great development prospects. Summary of the invention

[0005] The purpose of the present invention is to provide a method for preparing a water-soluble activatable chemiluminescent imaging probe and its in vivo imaging application.

[0006] To achieve the above purpose, the technical solution adopted by the present invention is as follows: A water-soluble activatable chemiluminescent nanoprobe, wherein the imaging and response elements of the water-soluble activatable chemiluminescent nanoprobe are porphyrin derivatives, the response target is peroxynitrite, and the detection signal is a near-infrared chemiluminescent signal; the porphyrin derivative is one or more of pyropheophorbide-a, dihydrochlorin e6, hematoporphyrin monomethyl ether, tetraphenylporphyrin, aminotetraphenylporphyrin, and tetrakis(4-carboxyphenyl)porphine; The particle size of the nanoprobe is 2-200 nm.

[0007] The preparation method of the above-mentioned water-soluble activatable chemiluminescent nanoprobe comprises the following steps: dissolving a porphyrin derivative containing a carboxyl group in DMSO, adding EDC∙HCl and NHS at room temperature, stirring for 2 hours to activate the carboxyl group, and obtaining an activated porphyrin derivative solution; dissolving a PEG derivative containing an amino group in DMSO, adding the mixture to the activated porphyrin derivative solution, stirring for 12 hours at room temperature, placing the mixture in a dialysis bag with a molecular weight cutoff of 3500Da, and dialyzing the mixture with ultrapure water for 48 hours to obtain a water-soluble activatable chemiluminescent nanoprobe; the porphyrin derivative containing a carboxyl group is one or more of pyropheophorbide-a, dihydrochlorin e6, tetrakis(4-carboxyphenyl)porphine, and hematoporphyrin monomethyl ether; the PEG derivative containing an amino group is one or more of PEG-NH2, 4-arm-PEG-NH2, and 8-arm-PEG-NH2, wherein the molecular weight of PEG is 500-5000; The mass ratio of the porphyrin derivative containing a carboxyl group to the PEG derivative containing an amino group is 2:25.

[0008] The preparation method of the above-mentioned water-soluble activatable chemiluminescent nanoprobe comprises the following steps: dissolving a PEG derivative containing a carboxyl group in DMSO, adding EDC∙HCl and NHS at room temperature, stirring for 2 hours to activate the carboxyl group, and obtaining an activated PEG derivative solution; dissolving a porphyrin derivative containing an amino group in DMSO, adding the solution to the activated PEG derivative solution, stirring for 12 hours at room temperature, placing the solution in a dialysis bag with a molecular weight cutoff of 3500Da, and dialyzing the solution with ultrapure water for 48 hours to obtain a water-soluble activatable chemiluminescent nanoprobe; the PEG derivative containing a carboxyl group is one or more of PEG-COOH, 4-arm-PEG-COOH, and 8-arm-PEG-COOH, wherein the molecular weight of PEG is 500-5000; the porphyrin derivative containing an amino group is aminotetraphenylporphyrin; The mass ratio of the PEG derivative containing a carboxyl group to the porphyrin derivative containing an amino group is 25:2.

[0009] The preparation method of the above-mentioned water-soluble activatable chemiluminescent nanoprobe comprises the following steps: dissolving a porphyrin derivative and a surfactant in tetrahydrofuran, adding the mixture dropwise into ultrapure water under ultrasonic conditions, ultrasonicating for 5 minutes, stirring for 2 hours, removing the solvent tetrahydrofuran by nitrogen blowing or rotary evaporation, and collecting the water-soluble activatable chemiluminescent nanoprobe by ultracentrifugation and ultrafiltration; the porphyrin derivative is tetraphenylporphyrin; the surfactant is one or more of distearoylphosphatidylethanolamine-polyethylene glycol, styrene-maleic anhydride copolymer, and polyether F127; The mass ratio of the porphyrin derivative to the surfactant is 0.1-1:5-50.

[0010] Use of the above-mentioned water-soluble activatable chemiluminescent nanoprobe in the preparation of a reagent for in vivo imaging and detection of peroxynitrite; The reagent for in vivo imaging and detection of peroxynitrite refers to a reagent for in vivo imaging and detection of changes in peroxynitrite content in inflammatory tissues and tumor tissues.

[0011] The present invention uses porphyrin derivatives as imaging and response elements to construct water-soluble, activatable chemiluminescent imaging nanoprobes; according to the different active groups of porphyrin derivative molecules (whether they contain carboxyl groups, amino groups and other active groups), covalent linking methods (reaction with PEG with amino groups or PEG with carboxyl groups) or nanoprecipitation methods (forming a stable body with surfactant molecules such as DSPE-PEG or PSMA or F127) are selected to synthesize different nanoprobes; and the nanoprobes are applied to high signal-to-noise ratio chemiluminescent imaging applications in living inflammation models or tumor models. The beneficial effects of the present invention are mainly reflected in the following aspects: (1) The synthesis steps of the peroxynitrite-responsive, water-soluble, activatable chemiluminescent nanoprobe of the present invention are simple, easy to operate, and highly reproducible; (2) The peroxynitrite-responsive nanoprobes of the present invention are stable, have hydrophilic protective groups on the surface, and have uniform particle size dispersion, thus ensuring their physiological stability and effectiveness; (3) The peroxynitrite-responsive nanoprobes of the present invention can specifically and sensitively respond to changes in peroxynitrite in inflammation and tumor microenvironment, produce sustained chemiluminescence, and achieve efficient signal-responsive disease diagnosis and imaging; they are free of excitation light and background fluorescence, and have a high signal-to-noise ratio (SBR). BRIEF DESCRIPTION OF THE DRAWINGS

[0012] Figure 1 : Chemical synthesis scheme for the preparation of PPA-PEG nanoprobes via amide coupling reaction.

[0013] Figure 2 : a is the particle size distribution diagram of the PPA-PEG nanoprobe; b is the Zeta potential diagram of the PPA-PEG nanoprobe; c is the transmission electron microscopy image of the PPA-PEG nanoprobe; d is the UV-visible absorption spectrum of the PPA-PEG nanoprobe; e is the FT-IR infrared spectrum of the PPA-PEG nanoprobe; f is the fluorescence spectrum of the PPA-PEG nanoprobe; g is the fluorescence stability analysis of the PPA monomer and the PPA-PEG nanoprobe in different solutions; h is the fluorescence intensity statistical diagram in g.

[0014] Figure 3 : Possible mechanism of chemiluminescence produced by PPA in response to peroxynitrite.

[0015] Figure 4 :a is the chemiluminescence image of PPA and PPA-PEG nanoprobes in water; b is the chemiluminescence response image of PPA-PEG nanoprobes after adding different ROS or solutions; c is the statistical graph of chemiluminescence intensity in b; de is the PPA-PEG nanoprobe to ONOO − The chemiluminescent signal response and chemiluminescence intensity (CL) and ONOO − The linear relationship between the concentration of PPA-PEG nanoprobe and ONOO − chemiluminescence response time; g and h are the chemiluminescence image and fluorescence image of the PPA-PEG nanoprobe covered with chicken tissue of different thicknesses, respectively; i is the result of the corresponding signal-to-noise ratio of the PPA-PEG nanoprobe from g and h.

[0016] Figure 5: a is the scheme of the ear inflammation induction method and its interaction with the PPA-PEG nanoprobe; b, c and d are in vivo chemiluminescence imaging of PPA-PEG nanoprobe signals in the ears of mice with LPS-induced inflammation at different times, intensities and fluorescence imaging; e, f and g are in vivo chemiluminescence imaging of PPA-PEG nanoprobe signals in the skin of mice treated with different treatments (normal saline, normal saline + PPA-PEG, LPS + PPA-PEG + GSH and LPS + PPA-PEG).

[0017] Figure 6 : a is the scheme of the method for inducing inflammation in the mouse back skin and its interaction with the PPA-PEG nanoprobe; b, c and d are the in vivo chemiluminescence imaging of the PPA-PEG nanoprobe signal in the mouse skin after LPS treatment, as well as the in vivo chemiluminescence imaging of the PPA-PEG signal after treatment with different concentrations of GSH, and the luminescence intensity was quantified.

[0018] Figure 7 : a is the scheme of PPA-PEG subcutaneous hepatocellular carcinoma (HCC) tumor model induction and tumor chemiluminescence imaging; b, c, d and e are the in vivo chemiluminescence imaging of PPA-PEG signals in the subcutaneous HCC tumor model at different times after nanoprobe injection, and the ex vivo chemiluminescence and fluorescence images of major organs and tumors were imaged 2 h after nanoprobe injection; f is the scheme of orthotopic implant HCC tumor model induction and PPA-PEG tumor chemiluminescence imaging; g, h, i and j are the in vivo chemiluminescence imaging of PPA-PEG signals in the orthotopic implant HCC tumor model injected intravenously, and the ex vivo chemiluminescence and fluorescence images of major organs and tumors were obtained 1 h after nanoprobe injection.

[0019] Figure 8 : Schematic illustration of the application of nanoprobes for chemiluminescent imaging of peroxynitrite in inflammation and tumors. DETAILED DESCRIPTION

[0020] In order to make the contents of the present invention easier to understand, the technical solution of the present invention is further described below in conjunction with specific implementation methods, but the present invention is not limited thereto.

[0021] The four-arm-polyethylene glycol-amino used in the following examples was purchased from the exploration platform, brand Adamas, item number 014241176. The four-arm-polyethylene glycol-carboxyl used in the following examples was purchased from the exploration platform, brand Adamas, item number 014241216. The distearoyl phosphatidylethanolamine-polyethylene glycol used in the following examples was purchased from Xi'an Ruixi Biological Co., Ltd., item number LP-R4-039.

[0022] Example 1: Synthesis of PPA-PEG Nanoprobes The synthesis scheme of PPA-PEG nanoprobes is as follows Figure 1 shown.

[0023] Step 1: Weigh 2 mg of pyropheophorbide-a (PPA) and dissolve it in 1 mL of DMSO. Add 5 mg of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC∙HCl) and 5 mg of N-hydroxysuccinimide (NHS) at room temperature and stir for 2 hours to activate the carboxyl group to obtain an activated PPA solution.

[0024] Step 2: Dissolve 25 mg of four-arm-polyethylene glycol-amino (4-arm-PEG-NH2) in 1 mL of DMSO, add it to the activated PPA solution obtained in step 1, stir at room temperature for 12 hours, place it in a dialysis bag with a molecular weight cutoff of 3500 Da and dialyze it with ultrapure water for 48 hours to remove the solvent DMSO, unreacted PPA, excess EDC∙HCl and NHS to obtain PPA-PEG nanoprobes, and store it at 4 °C in the dark for later use.

[0025] Example 2: Synthesis of TAPP-PEG Nanoprobes Step 1: Weigh 25 mg of four-arm-polyethylene glycol-carboxyl (4-arm-PEG-COOH) and dissolve it in 1 mL of DMSO. Add 5 mg of EDC∙HCl and 5 mg of NHS at room temperature and stir for 2 hours to activate the carboxyl group to obtain an activated 4-arm-PEG-COOH solution.

[0026] Step 2: Dissolve 2 mg of aminotetraphenylporphyrin (TAPP) in 1 mL of DMSO, add it to the activated 4-arm-PEG-COOH solution obtained in step 1, stir at room temperature for 12 hours, place it in a dialysis bag with a molecular weight cutoff of 3500 Da and dialyze it with ultrapure water for 48 hours to remove the solvent DMSO, unreacted TAPP, excess EDC∙HCl and NHS to obtain TAPP-PEG nanoprobes, and store it at 4 °C in the dark for later use.

[0027] Example 3: Synthesis of TPP nanoprobes 1 mg of tetraphenylporphyrin (TPP) and 20 mg of distearoylphosphatidylethanolamine-polyethylene glycol (DSPE-PEG) were weighed and dissolved in 1 mL of tetrahydrofuran (THF), and then added dropwise to 9 mL of ultrapure water under ultrasonic conditions. Ultrasonication was performed for 5 minutes and then stirred for 2 hours. The THF solvent was then removed by nitrogen blowing or rotary evaporation (100 rpm, 30°C) for 30 minutes. The nanoprobes were then collected by ultracentrifugation (30000 rpm, 30 minutes) or ultrafiltration method (20 KDa molecular weight cutoff, centrifugation at 3500 rpm for 20 minutes) and washed three times with ultrapure water.

[0028] Example 4: Characterization of PPA-PEG Nanoprobes The physical and chemical properties of the PPA-PEG nanoprobe synthesized in Example 1 were characterized by transmission electron microscopy, nanoparticle size and Zeta potential analyzer, UV-visible spectrophotometer, and fluorescence spectrometer (excitation wavelength of 650 nm).

[0029] Figure 2 a is the particle size distribution diagram of PPA-PEG nanoprobes. The results show that the size distribution is concentrated, indicating that the synthesized PPA-PEG nanoprobes are relatively uniform; Figure 2 b is the Zeta potential diagram of the PPA-PEG nanoprobe, with a potential of about 18 mV; Figure 2 c is the transmission electron microscopy image of PA-PEG nanoprobe, the size of PPA-PEG nanoprobe is about 5 nm; Figure 2 d is the UV-visible absorption spectrum of the PPA-PEG nanoprobe, which proves that the target probe has good hydrophilicity; Figure 2 e is the infrared spectrum of the PPA-PEG nanoprobe, where the characteristic peaks of 4-arm-PEG-NH2 and PPA can be observed, indicating that the nanoprobe was successfully synthesized; Figure 2 f is the fluorescence spectra of PPA-PEG nanoprobe and PPA. PPA itself emits very weak light, while the synthesized PPA-PEG nanoprobe emits strong light at 730 nm; Figure 2 g and 2h showed that the PPA-PEG nanoprobe (100 μg / mL) could maintain stability for 60 days in 9% NaCl, PBS, 0.9% NaCl and ddH2O, which proved that the present invention successfully constructed a nanoprobe with good stability and water solubility.

[0030] The luminescence mechanism of porphyrin derivative molecules in response to peroxynitrite is as follows Figure 3 As shown, it is mainly the vinyl bond in the porphyrin structure and ONOO - The reaction proceeds through orderly oxidation to form unstable dioxetane intermediates, which then emit chemiluminescence via energy transfer during the degradation process.

[0031] like Figure 4 As shown in a, compared with free PPA, PPA-PEG nanoprobes have good chemiluminescent properties; PPA-PEG nanoprobes (100 μg / mL) reacted with possible potential interferents (final concentration 100 μM, reaction time 5 minutes), and PPA-PEG nanoprobes reacted with ONOO - Has good selectivity ( Figure 4 b-4c), although hydroxyl radicals have signals, they are mainly produced during radiotherapy or chemodynamic therapy in the physiological environment and will not interfere with the in vivo application of this nanoprobe. PPA-PEG nanoprobe (100 μg / mL) can effectively respond to ONOO - Generates chemiluminescent signal, which increases with concentration, and has good linearity and high sensitivity in the concentration range (1-200 μM). Figure 4 d-4e), its response ONOO - (final concentration 100 μM) produces chemiluminescence for 60 minutes ( Figure 4 f); chicken tissues of different thicknesses (1-6 mm) were covered with nanoprobes and ONOO - The test response signal on the reaction well plate (final concentration 100 μM) simulated the chemiluminescent response phenomenon of the test probe in tissues at different depths, showing that the chemiluminescent phase transition to fluorescence has good penetration ability and high SBR ( Figure 4 g-4i), provides a promising tool for practical applications (cell or in vivo animal imaging).

[0032] Example 5: PPA-PEG Nanoprobes for Imaging ONOO in Inflammatory Tissues - Application of content and changes like Figure 5 As shown in a, lipopolysaccharide (LPS) was used to induce acute inflammation in the mouse skin. LPS (2 mg / mL, 25 μL) was injected into the skin of the right ear of the mouse for 12 h, and then PPA-PEG nanoprobes (500 μg / mL, 50 μL) were injected for further chemiluminescent imaging.

[0033] Figure 5 d Fluorescence imaging shows the injection site of the nanoprobe. Figure 5 As shown in b-5c, the chemiluminescent signal (chemiluminescent emission signal was collected by opening the filter, the acquisition time was 120 seconds) increased with time after the nanoprobe was injected and decreased after 4 hours, indicating the chemiluminescent imaging ability of PPA-PEG nanoprobe for LPS-induced inflammation; at the same time, glutathione (GSH) was used as ONOO - Scavenger, reducing ONOO -The contents of PPA-PEG nanoprobes were evaluated by in vivo chemiluminescent imaging of ONOO - After injection, mice were imaged on the IVIS luminescence imaging system in the bioluminescence imaging mode from 0 to 60 minutes. Figure 5 As shown in e-5f, the site treated with saline alone showed negligible signal, indicating that the background of chemiluminescent imaging mode was very low. However, the chemiluminescent signal of the site treated with LPS+PPA-PEG was stronger than that of saline+PPA-PEG, indicating that ONOO - In addition, the chemiluminescent signal of the site treated with LPS+PPA-PEG+GSH was weaker than that of LPS+PPA-PEG, indicating that GSH can reduce ONOO - concentration, indicating that PPA-PEG nanoprobes can be used for ONOO - Dynamic in vivo chemiluminescence imaging. Fluorescence imaging shows the injection sites of the four formulations ( Figure 5 g).

[0034] Evaluation of the therapeutic effect of GSH on inflammation by chemiluminescence imaging ( Figure 6 a): After 2 hours of acute skin inflammation induced by LPS (25 μL, 2 mg / mL), the inflammatory site was treated with different doses of GSH (0, 2, 4 mg in 25 μL saline) for 1 hour, and then chemiluminescence imaging was performed (chemiluminescence emission signals were collected through an open filter, and the acquisition time was 120 seconds). As shown in the figure, the chemiluminescence signal increased over time and lasted for more than 120 minutes after LPS injection. GSH treatment reduced the chemiluminescence signal. 2 mg of GSH can effectively scavenge ONOO - ( Figure 6 c-6d). Fluorescence imaging shows the nanoprobe injection site ( Figure 6 b).

[0035] Example 6: PPA-PEG Nanoprobe Imaging ONOO in Living Tumor Tissue - Application of content and changes Subcutaneous tumor model: Healthy male BALB / c57 mice were used for the experiment. The cultured Hepa1-6 cells were plated at 3×10 6 / mouse was inoculated into the right hind leg. Two weeks later, when the tumor grew to an appropriate size, the experiment was started. During the experiment, 10 g / L sodium pentobarbital dissolved in normal saline was used to anesthetize the mice.

[0036] The effect of PPA-PEG nanoprobes on in vivo tumor imaging in a subcutaneous tumor model was evaluated by intravenous injection in a low-background chemiluminescence mode. Figure 7 a). The chemiluminescent signal of the tumor increased over time and reached a peak at approximately 60 min after intravenous injection of the nanoprobe (500 μg / mL, 50 μL) ( Figure 7 b-7c). The chemiluminescent signal is generated by the interaction of the PPA-PEG nanoprobe with ONOO in the tumor. - The results showed that the PPA-PEG nanoprobe had good responsiveness and high signal-to-background ratio (SBR) for tumor chemiluminescence imaging. Figure 7 d) Tumors cannot be effectively distinguished. After in vivo imaging, mice were sacrificed and major organs and tumors were collected for ex vivo chemiluminescence and fluorescence imaging ( Figure 7 e), only the tumor tissue showed obvious chemiluminescent signals. In addition, an orthotopic model of mouse liver cancer was established: healthy male BALB / c57 mice were used for the experiment. The mice were fixed on the animal operating table, and the abdomen was opened layer by layer along the white line of the abdomen (about 1-2 cm incision), the abdominal cavity was exposed, the left liver was freed, and Hepa1-6 cells were injected under the liver capsule at a rate of 3.0×10 5 / were inoculated into the liver of mice, and the abdomen was sutured layer by layer after compression to stop bleeding. Aureomycin eye ointment was applied to the incision to prevent infection. Four weeks later, fluorescent live imaging experiments were started. During the experiment, 10 g / L sodium pentobarbital dissolved in saline was used to anesthetize the mice. The in vivo imaging ability of PPA-PEG nanoprobes was further evaluated in the orthotopic transplantation tumor model of mouse hepatocellular carcinoma ( Figure 7 f). Figure 7 As shown in g~7h, imaging was performed at 30 min, 40 min, 50 min, and 60 min after intravenous injection of the nanoprobe, and obvious chemiluminescent signals were collected from the liver of the orthotopic HCC mice, which showed a higher SBR than that of fluorescence imaging ( Figure 7 i). As with the intratumoral subcutaneous injection group, only the isolated tumor site showed obvious chemiluminescent signals compared with the main organs, while fluorescence imaging could hardly distinguish liver tumor tissue from normal liver ( Figure 7 j).

[0037] In summary, the PPA-PEG nanoprobe can rapidly and sensitively detect ONOO in inflammation and tumors in living mice with high SBR. - Perform imaging ( Figure 8 ), provides a tissue-free autofluorescence imaging mode for in vivo optical imaging, which will be beneficial to ONOO - Related in vivo biomedical research.

[0038] The above description is only a preferred embodiment of the present invention. All equivalent changes and modifications made according to the scope of the patent application of the present invention should fall within the scope of the present invention.

Claims

1. A water-soluble activatable chemiluminescent nanoprobe, characterized in that: The imaging and response elements of the water-soluble activatable chemiluminescent nanoprobe are porphyrin derivatives, the response target is peroxynitrite, and the detection signal is a near-infrared chemiluminescent signal; the porphyrin derivatives are one or more of pyropheophorbide-a, dihydrochlorin e6, hematoporphyrin monomethyl ether, tetraphenylporphyrin, aminotetraphenylporphyrin, and tetrakis(4-carboxyphenyl)porphine.

2. The water-soluble activatable chemiluminescent nanoprobe according to claim 1, characterized in that: The particle size of the nanoprobe is 2-200 nm.

3. A method for preparing a water-soluble activatable chemiluminescent nanoprobe according to any one of claims 1 to 2, characterized in that: A porphyrin derivative containing a carboxyl group is dissolved in DMSO, EDC∙HCl and NHS are added at room temperature, and stirred for 2 hours to activate the carboxyl group to obtain an activated porphyrin derivative solution; a PEG derivative containing an amino group is dissolved in DMSO, added to the activated porphyrin derivative solution, stirred at room temperature for 12 hours, placed in a dialysis bag with a molecular weight cutoff of 3500 Da, and dialyzed with ultrapure water for 48 hours to obtain a water-soluble activatable chemiluminescent nanoprobe; the porphyrin derivative containing a carboxyl group is one or more of pyropheophorbide-a, dihydrochlorin e6, tetrakis(4-carboxyphenyl)porphine, and hematoporphyrin monomethyl ether; the PEG derivative containing an amino group is one or more of PEG-NH2, 4-arm-PEG-NH2, and 8-arm-PEG-NH2, wherein the molecular weight of PEG is 500-5000.

4. The method for preparing the water-soluble activatable chemiluminescent nanoprobe according to claim 3, characterized in that: The mass ratio of the porphyrin derivative containing a carboxyl group to the PEG derivative containing an amino group is 2:

25.

5. A method for preparing a water-soluble activatable chemiluminescent nanoprobe according to any one of claims 1 to 2, characterized in that: A PEG derivative containing a carboxyl group is dissolved in DMSO, EDC∙HCl and NHS are added at room temperature, and the mixture is stirred for 2 hours to activate the carboxyl group, thereby obtaining an activated PEG derivative solution; a porphyrin derivative containing an amino group is dissolved in DMSO, added to the activated PEG derivative solution, stirred at room temperature for 12 hours, placed in a dialysis bag with a molecular weight cutoff of 3500 Da, and dialyzed with ultrapure water for 48 hours to obtain a water-soluble activatable chemiluminescent nanoprobe; the PEG derivative containing a carboxyl group is one or more of PEG-COOH, 4-arm-PEG-COOH, and 8-arm-PEG-COOH, wherein the molecular weight of PEG is 500-5000; and the porphyrin derivative containing an amino group is aminotetraphenylporphyrin.

6. The method for preparing the water-soluble activatable chemiluminescent nanoprobe according to claim 5, characterized in that: The mass ratio of the PEG derivative containing a carboxyl group to the porphyrin derivative containing an amino group is 25:

2.

7. A method for preparing a water-soluble activatable chemiluminescent nanoprobe according to any one of claims 1 to 2, characterized in that: The porphyrin derivative and the surfactant are dissolved in tetrahydrofuran, and the mixture is added dropwise into ultrapure water under ultrasonic conditions, and ultrasonicated for 5 minutes, and then stirred for 2 hours. After the solvent tetrahydrofuran is removed by nitrogen blowing or rotary evaporation, the water-soluble activatable chemiluminescent nanoprobe is collected by ultracentrifugation and ultrafiltration. The porphyrin derivative is tetraphenylporphyrin; and the surfactant is one or more of distearoylphosphatidylethanolamine-polyethylene glycol, styrene-maleic anhydride copolymer, and polyether F127.

8. The method for preparing the water-soluble activatable chemiluminescent nanoprobe according to claim 7, characterized in that: The mass ratio of the porphyrin derivative to the surfactant is 0.1-1:5-50.

9. Use of the water-soluble, activatable chemiluminescent nanoprobe according to any one of claims 1 to 2 in the preparation of a reagent for in vivo imaging and detection of peroxynitrite.

10. Use of the water-soluble activatable chemiluminescent nanoprobe according to claim 9 in the preparation of a reagent for in vivo imaging and detection of peroxynitrite, characterized in that: The reagent for in vivo imaging and detection of peroxynitrite refers to a reagent for in vivo imaging and detection of changes in peroxynitrite content in inflammatory tissues and tumor tissues.